A citation-based method for searching scientific literature

M E Brunkow, J C Gardner, J Van Ness, B W Paeper, B R Kovacevich, S Proll, J E Skonier, L Zhao, P J Sabo, Y Fu, R S Alisch, L Gillett, T Colbert, P Tacconi, D Galas, H Hamersma, P Beighton, J Mulligan. Am J Hum Genet 2001
Times Cited: 675







List of co-cited articles
923 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).
W Balemans, M Ebeling, N Patel, E Van Hul, P Olson, M Dioszegi, C Lacza, W Wuyts, J Van Den Ende, P Willems,[...]. Hum Mol Genet 2001
784
53

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.
W Balemans, N Patel, M Ebeling, E Van Hul, W Wuyts, C Lacza, M Dioszegi, F G Dikkers, P Hildering, P J Willems,[...]. J Med Genet 2002
489
34

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Felicia Cosman, Daria B Crittenden, Jonathan D Adachi, Neil Binkley, Edward Czerwinski, Serge Ferrari, Lorenz C Hofbauer, Edith Lau, E Michael Lewiecki, Akimitsu Miyauchi,[...]. N Engl J Med 2016
630
32

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
Xiaodong Li, Michael S Ominsky, Qing-Tian Niu, Ning Sun, Betsy Daugherty, Diane D'Agostin, Carole Kurahara, Yongming Gao, Jin Cao, Jianhua Gong,[...]. J Bone Miner Res 2008
644
31

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Xiaofeng Li, Yazhou Zhang, Heeseog Kang, Wenzhong Liu, Peng Liu, Jianghong Zhang, Stephen E Harris, Dianqing Wu. J Biol Chem 2005
901
29

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Kenneth G Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C Karaplis, Mattias Lorentzon, Thierry Thomas, Judy Maddox, Michelle Fan, Paul D Meisner, Andreas Grauer. N Engl J Med 2017
468
28

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
David G Winkler, May Kung Sutherland, James C Geoghegan, Changpu Yu, Trenton Hayes, John E Skonier, Diana Shpektor, Mechtild Jonas, Brian R Kovacevich, Karen Staehling-Hampton,[...]. EMBO J 2003
716
27

Romosozumab in postmenopausal women with low bone mineral density.
Michael R McClung, Andreas Grauer, Steven Boonen, Michael A Bolognese, Jacques P Brown, Adolfo Diez-Perez, Bente L Langdahl, Jean-Yves Reginster, Jose R Zanchetta, Scott M Wasserman,[...]. N Engl J Med 2014
677
22


SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
Mikhail Semënov, Keiko Tamai, Xi He. J Biol Chem 2005
532
19

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Kenneth E S Poole, Rutger L van Bezooijen, Nigel Loveridge, Herman Hamersma, Socrates E Papapoulos, Clemens W Löwik, Jonathan Reeve. FASEB J 2005
607
18

LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
Y Gong, R B Slee, N Fukai, G Rawadi, S Roman-Roman, A M Reginato, H Wang, T Cundy, F H Glorieux, D Lev,[...]. Cell 2001
18

High bone density due to a mutation in LDL-receptor-related protein 5.
Lynn M Boyden, Junhao Mao, Joseph Belsky, Lyle Mitzner, Anita Farhi, Mary A Mitnick, Dianqing Wu, Karl Insogna, Richard P Lifton. N Engl J Med 2002
18

Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.
Olivier Leupin, Elke Piters, Christine Halleux, Shouih Hu, Ina Kramer, Frederic Morvan, Tewis Bouwmeester, Markus Schirle, Manuel Bueno-Lozano, Feliciano J Ramos Fuentes,[...]. J Biol Chem 2011
185
16

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.
Randall D Little, John P Carulli, Richard G Del Mastro, Josée Dupuis, Mark Osborne, Colleen Folz, Susan P Manning, Pamela M Swain, Shan-Chuan Zhao, Brenda Eustace,[...]. Am J Hum Genet 2002
898
16

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Xiaodong Li, Michael S Ominsky, Kelly S Warmington, Sean Morony, Jianhua Gong, Jin Cao, Yongming Gao, Victoria Shalhoub, Barbara Tipton, Raj Haldankar,[...]. J Bone Miner Res 2009
562
16

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.
Desmond Padhi, Graham Jang, Brian Stouch, Liang Fang, Edward Posvar. J Bone Miner Res 2011
528
16

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Bente L Langdahl, Cesar Libanati, Daria B Crittenden, Michael A Bolognese, Jacques P Brown, Nadia S Daizadeh, Eva Dokoupilova, Klaus Engelke, Joel S Finkelstein, Harry K Genant,[...]. Lancet 2017
171
16

A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
E Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere, Kurt Lippuner, Paul D Meisner, Paul D Miller, Akimitsu Miyauchi, Judy Maddox, Li Chen, Stephane Horlait. J Clin Endocrinol Metab 2018
93
17

Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Asiri R Wijenayaka, Masakazu Kogawa, Hui Peng Lim, Lynda F Bonewald, David M Findlay, Gerald J Atkins. PLoS One 2011
298
15

Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.
Alexander G Robling, Paul J Niziolek, Lee A Baldridge, Keith W Condon, Matthew R Allen, Imranul Alam, Sara M Mantila, Jelica Gluhak-Heinrich, Teresita M Bellido, Stephen E Harris,[...]. J Biol Chem 2008
840
14

Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Chuwen Lin, Xuan Jiang, Zhongquan Dai, Xizhi Guo, Tujun Weng, Jun Wang, Yinghui Li, Guoyin Feng, Xiang Gao, Lin He. J Bone Miner Res 2009
425
13

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.
Gabriela G Loots, Michaela Kneissel, Hansjoerg Keller, Myma Baptist, Jessie Chang, Nicole M Collette, Dmitriy Ovcharenko, Ingrid Plajzer-Frick, Edward M Rubin. Genome Res 2005
303
13

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
Rutger L van Bezooijen, Bernard A J Roelen, Annemieke Visser, Lianne van der Wee-Pals, Edwin de Wilt, Marcel Karperien, Herman Hamersma, Socrates E Papapoulos, Peter ten Dijke, Clemens W G M Löwik. J Exp Med 2004
567
12

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Donald A Glass, Peter Bialek, Jong Deok Ahn, Michael Starbuck, Millan S Patel, Hans Clevers, Mark M Taketo, Fanxin Long, Andrew P McMahon, Richard A Lang,[...]. Dev Cell 2005
12

Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.
Xiaolin Tu, Yumie Rhee, Keith W Condon, Nicoletta Bivi, Matthew R Allen, Denise Dwyer, Marina Stolina, Charles H Turner, Alexander G Robling, Lilian I Plotkin,[...]. Bone 2012
296
12

The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells.
Dongxing Zhu, Neil Charles Wallace Mackenzie, José Luis Millán, Colin Farquharson, Vicky Elizabeth MacRae. PLoS One 2011
189
12

Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis.
John P Kemp, John A Morris, Carolina Medina-Gomez, Vincenzo Forgetta, Nicole M Warrington, Scott E Youlten, Jie Zheng, Celia L Gregson, Elin Grundberg, Katerina Trajanoska,[...]. Nat Genet 2017
204
12

Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21.
W Balemans, J Van Den Ende, A Freire Paes-Alves, F G Dikkers, P J Willems, F Vanhoenacker, N de Almeida-Melo, C F Alves, C A Stratakis, S C Hill,[...]. Am J Hum Genet 1999
81
13

Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation.
Vaclav Veverka, Alistair J Henry, Patrick M Slocombe, Andrew Ventom, Barbara Mulloy, Frederick W Muskett, Mariusz Muzylak, Kevin Greenslade, Adrian Moore, Li Zhang,[...]. J Biol Chem 2009
164
11

An atlas of genetic influences on osteoporosis in humans and mice.
John A Morris, John P Kemp, Scott E Youlten, Laetitia Laurent, John G Logan, Ryan C Chai, Nicholas A Vulpescu, Vincenzo Forgetta, Aaron Kleinman, Sindhu T Mohanty,[...]. Nat Genet 2019
251
11

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Robert R Recker, Charles T Benson, Toshio Matsumoto, Michael A Bolognese, Deborah A Robins, Jahangir Alam, Alan Y Chiang, Leijun Hu, John H Krege, Hideaki Sowa,[...]. J Bone Miner Res 2015
178
11

Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.
Liesbeth Van Wesenbeeck, Erna Cleiren, Jeppe Gram, Rodney K Beals, Olivier Bénichou, Domenico Scopelliti, Lyndon Key, Tara Renton, Cindy Bartels, Yaoqin Gong,[...]. Am J Hum Genet 2003
396
10

Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures.
Sofia Movérare-Skrtic, Petra Henning, Xianwen Liu, Kenichi Nagano, Hiroaki Saito, Anna E Börjesson, Klara Sjögren, Sara H Windahl, Helen Farman, Bert Kindlund,[...]. Nat Med 2014
199
10

Sclerostin deficiency in humans.
Antoon H van Lierop, Natasha M Appelman-Dijkstra, Socrates E Papapoulos. Bone 2017
44
22

A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone.
Igor Fijalkowski, Ellen Geets, Ellen Steenackers, Viviane Van Hoof, Feliciano J Ramos, Geert Mortier, Ana Maria Fortuna, Wim Van Hul, Eveline Boudin. J Bone Miner Res 2016
38
26


Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
Michael R McClung, Jacques P Brown, Adolfo Diez-Perez, Heinrich Resch, John Caminis, Paul Meisner, Michael A Bolognese, Stefan Goemaere, Henry G Bone, Jose R Zanchetta,[...]. J Bone Miner Res 2018
85
11

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Michael S Ominsky, Fay Vlasseros, Jacquelin Jolette, Susan Y Smith, Brian Stouch, George Doellgast, Jianhua Gong, Yongming Gao, Jin Cao, Kevin Graham,[...]. J Bone Miner Res 2010
301
10

Evidence for osteocyte regulation of bone homeostasis through RANKL expression.
Tomoki Nakashima, Mikihito Hayashi, Takanobu Fukunaga, Kosaku Kurata, Masatsugu Oh-Hora, Jian Q Feng, Lynda F Bonewald, Tatsuhiko Kodama, Anton Wutz, Erwin F Wagner,[...]. Nat Med 2011
985
9

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture.
Karol Estrada, Unnur Styrkarsdottir, Evangelos Evangelou, Yi-Hsiang Hsu, Emma L Duncan, Evangelia E Ntzani, Ling Oei, Omar M E Albagha, Najaf Amin, John P Kemp,[...]. Nat Genet 2012
781
9

Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis.
Kyu Sang Joeng, Yi-Chien Lee, Joohyun Lim, Yuqing Chen, Ming-Ming Jiang, Elda Munivez, Catherine Ambrose, Brendan H Lee. J Clin Invest 2017
100
9

Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways.
Carola Krause, Olexandr Korchynskyi, Karien de Rooij, Stella E Weidauer, David J J de Gorter, Rutger L van Bezooijen, Sarah Hatsell, Aris N Economides, Thomas D Mueller, Clemens W G M Löwik,[...]. J Biol Chem 2010
120
9

Sclerostin expression and functions beyond the osteocyte.
Megan M Weivoda, Stephanie J Youssef, Merry Jo Oursler. Bone 2017
61
14

Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study.
Vincent M Brandenburg, Rafael Kramann, Ralf Koos, Thilo Krüger, Leon Schurgers, Georg Mühlenbruch, Sinah Hübner, Ulrich Gladziwa, Christiane Drechsler, Markus Ketteler. BMC Nephrol 2013
110
9

Mutations in WNT1 cause different forms of bone fragility.
Katharina Keupp, Filippo Beleggia, Hülya Kayserili, Aileen M Barnes, Magdalena Steiner, Oliver Semler, Björn Fischer, Gökhan Yigit, Claudia Y Janda, Jutta Becker,[...]. Am J Hum Genet 2013
175
9

WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk.
Hou-Feng Zheng, Jon H Tobias, Emma Duncan, David M Evans, Joel Eriksson, Lavinia Paternoster, Laura M Yerges-Armstrong, Terho Lehtimäki, Ulrica Bergström, Mika Kähönen,[...]. PLoS Genet 2012
175
9

New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
Michael P Whyte, William H McAlister, Fan Zhang, Vinieth N Bijanki, Angela Nenninger, Gary S Gottesman, Elizabeth L Lin, Margaret Huskey, Shenghui Duan, Kathryn Dahir,[...]. Bone 2019
22
40

Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors.
Gill Holdsworth, Patrick Slocombe, Carl Doyle, Bernadette Sweeney, Vaclav Veverka, Kelly Le Riche, Richard J Franklin, Joanne Compson, Daniel Brookings, James Turner,[...]. J Biol Chem 2012
58
13

Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
Scott Taylor, Michael S Ominsky, Rong Hu, Efrain Pacheco, Yudong D He, Danielle L Brown, J Ignacio Aguirre, Thomas J Wronski, Sabina Buntich, Cynthia A Afshari,[...]. Bone 2016
62
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.